盘龙药业(002864) - 盘龙药业调研活动信息

Group 1: Research and Development Progress - The 3CL protease inhibitor project is in the preclinical research phase, developed in collaboration with Shaanxi University of Science and Technology [2] - The Qingfeng Hupai granules, based on traditional Chinese medicine, target mild COVID-19 symptoms and have been approved as a hospital preparation in Shaanxi Province [2][3] - The company signed a technical development contract with Shaanxi Traditional Chinese Medicine Research Institute to develop new herbal medicines for flu [3] Group 2: Product Development and Production - The company has expanded its production capabilities to include nine types of traditional Chinese medicine formulations, enhancing its competitive edge in hospital preparations [4] - The establishment of the Shaanxi Medical Institution Preparation Centralized Preparation Center has facilitated the signing of multiple processing agreements with medical institutions [4] - The company is developing transdermal drug delivery systems, including gel patches and hot melt adhesive patches, to enhance its product line [3] Group 3: Market Expansion and Sales Strategy - The company has established a comprehensive marketing network across 31 provinces, ensuring steady growth in performance [5] - The health product line includes six major categories, with significant sales growth driven by both online and offline channels [5] - The company is actively expanding into large supermarket markets and building specialized marketing teams [5] Group 4: Logistics and Distribution - The company’s pharmaceutical distribution network covers thousands of medical institutions in Shaanxi Province, ensuring comprehensive service delivery [6] - The company has obtained drug distribution rights through compliance with national quality management standards [6] - The logistics operations have seen steady growth, particularly during the pandemic, ensuring timely delivery of medical supplies [6] Group 5: Profitability and Future Planning - The company is focused on improving profitability through various strategies, including stabilizing raw material costs and optimizing product structure [6] - Plans include expanding the health business segment to create new profit growth points [6] - The company aims to enhance its research and development capabilities to foster innovative projects [6]